{
    "url_original": "https://www.wsj.com/articles/u-s-boosts-order-for-glaxos-covid-19-antibody-drug-11637145631?mod=business_lead_pos3",
    "url": "u-s-boosts-order-for-glaxos-covid-19-antibody-drug-11637145631",
    "title": "U.S. Boosts Order for Glaxo’s Covid-19 Antibody Drug",
    "sub_head": "Purchase will expand availability of a type of treatment that has proven useful in reducing hospitalizations",
    "category_1": "Business",
    "time": "2021-11-17 05:40:00",
    "body": "The U.S. government has agreed to buy more doses of an antibody drug for the early treatment of Covid-19 developed by  GlaxoSmithKline  PLC and  Vir Biotechnology Inc.,  bringing its total order to nearly $1 billion for a treatment found to reduce the risk of hospitalization.<br />Even as vaccination rates tick up, antibody drugs, which imitate part of the body’s natural immune response to the virus, have proven useful in fighting Covid-19 and preventing hospitals from being overwhelmed when cases surge."
}